Citizens Jmp Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

Citizens Jmp lowered shares of Vigil Neuroscience (NASDAQ:VIGL) from a strong-buy rating to a hold rating in a research note published on Thursday morning,Zacks.com reports.

VIGL has been the subject of a number of other research reports. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the company a “neutral” rating in a research report on Thursday. Jefferies Financial Group cut Vigil Neuroscience to a “hold” rating in a research note on Thursday. William Blair downgraded Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. HC Wainwright dropped their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Finally, Citigroup downgraded shares of Vigil Neuroscience to a “market perform” rating in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Vigil Neuroscience has an average rating of “Hold” and a consensus price target of $13.00.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL opened at $7.88 on Thursday. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The stock has a market capitalization of $367.78 million, a P/E ratio of -3.83 and a beta of 1.90. The company’s 50-day moving average is $2.07 and its 200 day moving average is $2.27.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Research analysts anticipate that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Trading of Vigil Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of VIGL. Cubist Systematic Strategies LLC lifted its holdings in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new position in Vigil Neuroscience in the 4th quarter worth about $83,000. Barclays PLC lifted its stake in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after acquiring an additional 19,436 shares during the period. Northern Trust Corp lifted its stake in Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after acquiring an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in shares of Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after acquiring an additional 49,000 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.